home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630113.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
3KB
|
47 lines
Document 0113
DOCN M9630113
TI Domains of the human immunodeficiency virus type 1 matrix and gp41
cytoplasmic tail required for envelope incorporation into virions.
DT 9603
AU Freed EO; Martin MA; Laboratory of Molecular Microbiology, National
Institute of; Allergy and Infectious Diseases, Bethesda, Maryland
20892-0460,; USA.
SO J Virol. 1996 Jan;70(1):341-51. Unique Identifier : AIDSLINE
MED/96099449
AB We recently demonstrated that a single amino acid substitution in matrix
residue 12 (12LE) or 30 (30LE) blocks the incorporation of human
immunodeficiency virus type 1 (HIV-1) envelope glycoproteins into
virions and that this block can be reversed by pseudotyping with
heterologous retroviral envelope glycoproteins with short cytoplasmic
tails or by truncating the cytoplasmic tail of HIV-1 transmembrane
glycoprotein gp41 by 104 or 144 amino acids. In this study, we mapped
the domain of the gp41 cytoplasmic tail responsible for the block to
incorporation into virions by introducing a series of eight truncation
mutations that eliminated 23 to 93 amino acids from the C terminus of
gp41. We found that incorporation into virions of a HIV-1 envelope
glycoprotein with a deletion of 23, 30, 51, or 56 residues from the C
terminus of gp41 is specifically blocked by the 12LE matrix mutation,
whereas truncations of greater than 93 amino acids reverse this defect.
To elucidate the role of matrix residue 12 in this process, we
introduced a number of additional single amino acid substitutions at
matrix positions 12 and 13. Charged substitutions at residue 12 blocked
envelope incorporation and virus infectivity, whereas more subtle amino
acid substitutions resulted in a spectrum of envelope incorporation
defects. To characterize further the role of matrix in envelope
incorporation into virions, we obtained and analyzed second-site
revertants to two different matrix residue 12 mutations. A Val-->Ile
substition at matrix amino acid 34 compensated for the effects of both
amino acid 12 mutations, suggesting that matrix residues 12 and 34
interact during the incorporation of HIV-1 envelope glycoproteins into
nascent virions.
DE Amino Acid Sequence Base Sequence Binding Sites Cell Line DNA, Viral
Gene Products, env/METABOLISM Gene Products, gag/CHEMISTRY/*METABOLISM
Hela Cells Human HIV Antigens/CHEMISTRY/*METABOLISM HIV Envelope
Protein gp41/CHEMISTRY/*METABOLISM HIV-1/*METABOLISM Molecular
Sequence Data Mutagenesis Mutation Protein Precursors/METABOLISM
Viral Envelope Proteins/*METABOLISM Virion/METABOLISM JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).